Back to Search
Start Over
Factors potentially associated with gemcitabine-based chemotherapy-induced thrombocytopenia in Chinese patients with nonsmall cell lung cancer.
- Source :
-
Journal of cancer research and therapeutics [J Cancer Res Ther] 2018 Sep; Vol. 14 (Supplement), pp. S656-S660. - Publication Year :
- 2018
-
Abstract
- Objective: To investigate the prevalence and characteristics of gemcitabine-based chemotherapy-induced thrombocytopenia in Chinese patients with nonsmall cell lung cancer (NSCLC).<br />Materials and Methods: Medical records of 197 patients with histologically proven NSCLC received gemcitabine-based chemotherapy from June 2011 to June 2013 in our hospital were collected. The relative risk factors were identified and evaluated by univariate and multivariate analyses.<br />Results: The incidence of gemcitabine-based chemotherapy-induced thrombocytopenia in these NSCLC patients was 85.8%. Between thrombocytopenia and nonthrombocytopenia patients, in patients with thrombocytopenia and thrombocytopenia, we found Stage III/IV patients got more probabilities for thrombocytopenia (P < 0.01). In addition, patients who received gemcitabine and cisplatin (GP) regimen resulted in more thrombocytopenia than gemcitabine and carboplatin (GC) and other regimens (P < 0.001). In addition, majority of the thrombocytopenia patients presented thrombocytopenia in their first cycle (P < 0.001). Whereas, other potential risk factors such as age, gender, performance status value, diabetes mellitus or not, and other underlying disease (hypertension and hepatopathy) were not showed such significance in this study. Further, the multivariate analysis revealed that stage (odds ratio [OR] 7.113, P < 0.01) and chemotherapy cycles (OR 0.543, P < 0.01) were also statistically significant independent risk factors for gemcitabine-based chemotherapy-induced thrombocytopenia.<br />Conclusion: This study shows that thrombocytopenia is common in Chinese NSCLC patients receiving gemcitabine-based regimens. Chemotherapy cycles and stage might be the important factors influencing the occurrence of gemcitabine-based regimens-induced thrombocytopenia.<br />Competing Interests: There are no conflicts of interest
- Subjects :
- Adult
Aged
Carcinoma, Non-Small-Cell Lung complications
Carcinoma, Non-Small-Cell Lung epidemiology
Carcinoma, Non-Small-Cell Lung pathology
China epidemiology
Cisplatin therapeutic use
Deoxycytidine adverse effects
Deoxycytidine therapeutic use
Female
Humans
Male
Medical Records
Middle Aged
Neoplasm Staging
Risk Factors
Thrombocytopenia chemically induced
Thrombocytopenia epidemiology
Treatment Outcome
Gemcitabine
Carcinoma, Non-Small-Cell Lung drug therapy
Cisplatin adverse effects
Deoxycytidine analogs & derivatives
Thrombocytopenia pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1998-4138
- Volume :
- 14
- Issue :
- Supplement
- Database :
- MEDLINE
- Journal :
- Journal of cancer research and therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 30249883
- Full Text :
- https://doi.org/10.4103/0973-1482.187338